Cancer trial seeks to replace harsh chemo with immunotherapy

This large Phase 3 trial is testing whether a gentler treatment approach works as well as standard care for advanced nasopharyngeal cancer. Researchers want to see if they can replace harsh concurrent chemotherapy with immunotherapy (serplulimab) after initial chemotherapy, aiming to maintain cancer control while reducing severe side effects like vomiting. The study will enroll 456 patients who respond well to initial treatment and compare survival rates and quality of life between the two approaches.